This Dow Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded several companies: Roth Capital cut SoundThinking (SSTI) to Neutral with a $9 target, Citigroup downgraded Moderna (MRNA) to Sell with an $80 target, TD Cowen downgraded Accelerant (ARX) to Hold with a $20.25 target, Barclays downgraded Mobileye (MBLY) to Equal-Weight with a $9 target, and Citigroup downgraded Dow (DOW) to Neutral with a $30 target.
How this was made
The 30-second read
Why it matters
The downgrades collectively suggest a modest bearish bias across the listed stocks, though individual target adjustments vary.
Market read
The article aggregates recent analyst downgrades, offering traders a snapshot of potential short-term pressure on five U.S.-listed stocks.
What to watch
Potential upcoming product launches or pipeline news could offset the negative rating impact.
Background
Analyst rating changes are a common catalyst for short-term price moves, especially when accompanied by new price targets.
Ticker impact
Roth Capital downgraded SoundThinking Inc from Buy to Neutral with a new $9 price target.
likely pressure as the market prices in the downgrade and lower target.
Analyst downgrade and reduced price target typically lead to short-term sell pressure.
Citigroup downgraded Moderna Inc from Neutral to Sell and raised the price target from $60 to $80.
possible modest pressure from the downgrade despite the higher target.
Downgrade signals concerns, but the raised target suggests some upside potential, creating uncertainty.
TD Cowen downgraded Accelerant Holdings from Buy to Hold and cut the price target to $20.25.
likely pressure as investors adjust expectations to the lower target.
Hold rating and lower target reduce bullish sentiment.
Barclays downgraded Mobileye Global Inc from Overweight to Equal-Weight and lowered the price target to $9.
likely pressure as the market absorbs the downgrade.
Equal-Weight suggests a neutral stance, but the lower target may trigger short-term selling.
Citigroup downgraded Dow Inc from Buy to Neutral and lowered the price target to $30.
likely pressure as investors react to the downgrade.
Neutral rating and lower target diminish bullish outlook.
Market effects
Analyst rating changes may affect the broader tech and materials sectors as peers adjust expectations.
U.S. equity markets may see modest downside pressure in the affected stocks.
Limited to U.S.-listed companies; minimal global impact.
Counterpoint
Some investors may view the higher price targets (e.g., Moderna) as a buying opportunity despite the downgrade.
Key entities
- Analyst FirmRoth Capital
Provided downgrade for SSTI.
- Analyst FirmCitigroup
Downgraded MRNA and DOW.
- Analyst FirmTD Cowen
Downgraded ARX.
- Analyst FirmBarclays
Downgraded MBLY.
